Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VELTASSA vs LOKELMA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.
Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.
Treatment of hyperkalemia,Off-label: Management of hyperkalemia in patients on renin-angiotensin-aldosterone system inhibitors
Treatment of hyperkalemia,Off-label: Management of hyperkalemia in patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors
8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.
5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).
Not applicable due to non-systemic action; patiromer acts locally in the gastrointestinal tract and is not absorbed. Elimination half-life of the polymer is not measurable clinically.
Not applicable as LOKELMA is not systemically absorbed; terminal half-life is not measurable in traditional sense. Clinical effect duration correlates with gastrointestinal transit time (~6-8 hours for peak potassium lowering).
Not metabolized; eliminated unchanged in feces.
Patiromer is not absorbed systemically and not metabolized; it is excreted unchanged in feces.
Primarily eliminated via feces as insoluble, non-absorbed polymer (80-90%); minimal renal excretion (<0.01% of administered dose as intact drug in urine), biliary excretion negligible.
Primarily eliminated unchanged in feces (approximately 90%) via gastrointestinal transit; <1% excreted in urine as absorbed sodium zirconium cyclosilicate is negligible.
Not absorbed, therefore protein binding is not applicable; the drug is not systemically available.
Not bound to plasma proteins as it is non-absorbed and acts locally in the gastrointestinal tract.
Not applicable (non-systemic); Vd cannot be measured as the drug is not absorbed into systemic circulation.
Not applicable (locally acting, non-absorbed); apparent Vd is negligible due to lack of systemic absorption.
Negligible (<0.01%) after oral administration; patiromer acts locally and is not absorbed due to high molecular weight and non-digestible polymer structure.
Oral bioavailability is <1% as the drug is not absorbed from the gastrointestinal tract.
No dose adjustment is required for mild to moderate renal impairment (e GFR 30-89 m L/min/1.73 m²). For severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis-dependent patients, use with caution; starting dose 8.4 g once daily with close monitoring of serum potassium.
No dose adjustment required based on GFR; monitor serum potassium more frequently in patients with e GFR <30 m L/min/1.73m² due to increased risk of hypokalemia.
No specific dose adjustment recommended for Child-Pugh Class A or B. For Child-Pugh Class C (severe hepatic impairment), use with caution due to lack of data; no dose adjustment proposed.
No dose adjustment required for Child-Pugh Class A, B, or C; use with caution in severe hepatic impairment due to limited data.
Safety and efficacy have not been established in pediatric patients (age <18 years). No recommended dosing.
Safety and efficacy not established in pediatric patients; no approved dosing recommendations.
No specific dose adjustment required. Elderly patients may have decreased renal function; monitor serum potassium and renal function periodically.
No specific dose adjustment; monitor serum potassium and renal function due to age-related decline in renal function and increased risk of hypokalemia.
None
None
Bowel obstruction or perforation risk in patients with gastrointestinal disorders,Severe constipation,Hypomagnesemia,Increased risk of gastrointestinal adverse events when used with certain drugs
WARNING: Risk of hypomagnesemia; monitor serum magnesium. WARNING: Potential for gastrointestinal obstruction or perforation; use with caution in patients with severe gastrointestinal disorders. WARNING: May bind to other oral medications; separate dosing by at least 3 hours (or 6 hours for certain drugs).
Known hypersensitivity to patiromer,Severe constipation,Obstructive bowel disorders,Ileus or bowel perforation
Absolute: Hypersensitivity to patiromer or any excipient. Relative: Severe constipation, bowel obstruction, or impaction; postoperative gastrointestinal surgery.
Take with food to improve tolerability. No specific dietary restrictions beyond standard potassium management. Avoid high-potassium foods if directed by physician.
LOKELMA should be taken with food to reduce gastrointestinal side effects. No specific food restrictions, but high-potassium foods should be avoided as per dietary guidelines for hyperkalemia.
FDA Pregnancy Category C. In animal reproduction studies, patiromer administered to pregnant rats and rabbits at doses up to 10 times the human clinical dose (6.3 g/day) showed no evidence of fetal harm. However, no adequate and well-controlled studies in pregnant women. Potential risks: maternal electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) may pose fetal risk; use only if clearly needed.
No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer), systemic absorption is minimal; fetal exposure unlikely. However, no controlled data. Use only if clearly needed and potential benefit justifies potential risk to fetus.
No data on presence in human milk, effects on breastfed infant, or milk production. Patiromer is a non-absorbed polymer; systemic absorption is negligible (<0.001%), so minimal excretion into breast milk is expected. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need.
No data on presence in human milk, effects on breastfed infant, or on milk production. Given negligible oral absorption, excretion into breast milk is expected to be minimal. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need.
No specific dose adjustments recommended based on pharmacokinetic changes in pregnancy. Patiromer is not systemically absorbed; pregnancy-induced changes in GI motility or transit time are unlikely to affect efficacy. Dose should be guided by serum potassium levels, with caution due to potential electrolyte disturbances.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on current data. Use lowest effective dose to normalize potassium levels. Monitor potassium closely as pregnancy may alter electrolyte balance.
VELTASSA (patiromer) is a non-absorbed potassium-binding polymer used for hyperkalemia. Administer at least 3 hours apart from other oral medications due to binding risk. Monitor serum potassium periodically; reduce dose or discontinue if hypokalemia occurs. Not for emergency treatment of life-threatening hyperkalemia due to slow onset. Avoid in patients with bowel obstruction or severe constipation.
LOKELMA (patiromer) is a non-absorbed potassium-binding polymer indicated for hyperkalemia. Administer at least 6 hours apart from other oral medications due to potential binding. Monitor serum potassium weekly until stable. May cause hypomagnesemia; check magnesium levels periodically. Use with caution in patients with gastrointestinal motility disorders.
Take exactly as prescribed, usually once daily with food.,Separate from other oral medications by at least 3 hours.,Mix powder with water (approximately 120 m L) and stir; drink immediately.,Do not heat or add to hot foods/liquids.,Contact doctor if experiencing constipation, severe stomach pain, or signs of low potassium (muscle cramps, weakness, irregular heartbeat).,Keep medication at room temperature; do not freeze.
Take LOKELMA exactly as prescribed, usually once daily with food.,Separate LOKELMA from other oral medications by at least 6 hours.,Do not crush, chew, or open capsules; swallow whole.,Notify your doctor if you experience constipation, nausea, or stomach pain.,Do not stop taking LOKELMA without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VELTASSA vs LOKELMA, answered by our medical review team.
VELTASSA is a Potassium Binder that works by VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.. LOKELMA is a Potassium Binder that works by Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VELTASSA and LOKELMA depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VELTASSA is: 8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.. The standard adult dose of LOKELMA is: 5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VELTASSA and LOKELMA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VELTASSA is classified as Category C. FDA Pregnancy Category C. In animal reproduction studies, patiromer administered to pregnant rats and rabbits at doses up to 10 times the human clinical dose (6.3 g/day) showed no . LOKELMA is classified as Category C. No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer). Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.